Janux Therapeutics, Inc. Common Stock (JANX) is a publicly traded Healthcare sector company. As of May 21, 2026, JANX trades at $14.15 with a market cap of $855.61M and a P/E ratio of -7.74. JANX moved +4.24% today. Year to date, JANX is +4.73%; over the trailing twelve months it is -43.31%. Its 52-week range spans $12.12 to $71.71. Analyst consensus is strong buy with an average price target of $39.79. Rallies surfaces JANX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Hedge funds tracked by Rallies that own JANX include Orbimed Advisors. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Janux Therapeutics, Inc. Common Stock.
| Metric | Value |
|---|---|
| Price | $14.15 |
| Market Cap | $855.61M |
| P/E Ratio | -7.74 |
| EPS | $-1.84 |
| Dividend Yield | 0.00% |
| 52-Week High | $71.71 |
| 52-Week Low | $12.12 |
| Volume | 931.95K |
| Avg Volume | 0 |
| Revenue (TTM) | $13.73M |
| Net Income | $-114.48M |
| Gross Margin | 0.00% |
15 analysts cover JANX: 0 strong buy, 13 buy, 1 hold, 1 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $39.79.